Published in RNA on August 13, 2007
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (2008) 1.70
Gene silencing in the marine diatom Phaeodactylum tricornutum. Nucleic Acids Res (2009) 1.67
Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci (2010) 1.33
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther (2009) 1.25
Novel RNA-based strategies for therapeutic gene silencing. Mol Ther (2010) 1.20
Selective gene silencing by viral delivery of short hairpin RNA. Virol J (2010) 1.17
Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA (2009) 1.16
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
Optimization of duplex stability and terminal asymmetry for shRNA design. PLoS One (2010) 1.05
Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA (2009) 1.02
The effects of stem length and core placement on shRNA activity. BMC Mol Biol (2011) 1.00
Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop (2008) 0.97
Improved siRNA/shRNA functionality by mismatched duplex. PLoS One (2011) 0.89
A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA (2011) 0.89
Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity. RNA (2014) 0.89
Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int J Biol Sci (2013) 0.88
Northern blotting analysis of microRNAs, their precursors and RNA interference triggers. BMC Mol Biol (2011) 0.85
RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev (2010) 0.84
Synthetic Pre-miRNA-Based shRNA as Potent RNAi Triggers. J Nucleic Acids (2011) 0.84
Molecular characteristics and efficacy of 16D10 siRNAs in inhibiting root-knot nematode infection in transgenic grape hairy roots. PLoS One (2013) 0.82
A simple and robust vector-based shRNA expression system used for RNA interference. PLoS One (2013) 0.82
Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100. BMC Biotechnol (2012) 0.79
Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods (2013) 0.79
Toward optimization of AgoshRNA molecules that use a non-canonical RNAi pathway: variations in the top and bottom base pairs. RNA Biol (2015) 0.79
Identification of loop nucleotide polymorphisms affecting microRNA processing and function. Mol Cells (2013) 0.78
Quantitative evaluation of first, second, and third generation hairpin systems reveals the limit of mammalian vector-based RNAi. RNA Biol (2016) 0.77
Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J Gene Med (2009) 0.77
Modulating APOBEC expression enhances DNA vaccine immunogenicity. Immunol Cell Biol (2015) 0.76
Evaluation of RNA-knockdown strategies for modulation of cytochrome P450 reductase activity in mouse hepatocytes. J RNAi Gene Silencing (2010) 0.76
Sensor and sensitivity: a screen for elite shRNAs. Mol Ther (2011) 0.76
Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA. Assay Drug Dev Technol (2015) 0.75
A new design of a lentiviral shRNA vector with inducible co-expression of ARGONAUTE 2 for enhancing gene silencing efficiency. Cell Biosci (2015) 0.75
Organic small hairpin RNAs (OshR): a do-it-yourself platform for transgene-based gene silencing. Methods (2013) 0.75
shRNA target prediction informed by comprehensive enquiry (SPICE): a supporting system for high-throughput screening of shRNA library. EURASIP J Bioinform Syst Biol (2016) 0.75
A streamlined method for the design and cloning of shRNAs into an optimized Dox-inducible lentiviral vector. BMC Biotechnol (2017) 0.75
Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing. Mol Ther Methods Clin Dev (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Transcription and processing of human microRNA precursors. Mol Cell (2004) 8.98
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A (2002) 8.57
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol (2002) 6.66
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65
Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol (2005) 5.60
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov (2004) 4.73
RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A (1998) 4.63
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J (2004) 4.54
Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol (2004) 3.67
Germline transmission of RNAi in mice. Nat Struct Biol (2003) 2.05
Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol (2005) 1.68
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett (2004) 1.30
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
Identification of the gene for vitamin K epoxide reductase. Nature (2004) 4.52
Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. J Biol Chem (2004) 4.32
Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A (2003) 3.74
Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol (2008) 3.72
Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta (2004) 3.47
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA (2006) 3.41
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 3.21
Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl (2012) 3.09
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
Detection of bladder cancer using a point-of-care proteomic assay. JAMA (2005) 2.88
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Druggability indices for protein targets derived from NMR-based screening data. J Med Chem (2005) 2.67
The flowering time regulator CONSTANS is recruited to the FLOWERING LOCUS T promoter via a unique cis-element. New Phytol (2010) 2.63
The contributions of dsRNA structure to Dicer specificity and efficiency. RNA (2005) 2.48
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem (2012) 2.23
Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA (2006) 2.17
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res (2008) 2.10
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem (2007) 2.09
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem (2004) 2.05
DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (2002) 2.04
Fast cleavage kinetics of a natural hammerhead ribozyme. J Am Chem Soc (2004) 2.00
Folding of the natural hammerhead ribozyme is enhanced by interaction of auxiliary elements. RNA (2004) 1.99
Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA (2008) 1.92
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem (2008) 1.85
RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A (2003) 1.84
Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA (2007) 1.83
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res (2007) 1.81
A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res (2004) 1.79
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr (2006) 1.73
The basic helix-loop-helix transcription factor PIF5 acts on ethylene biosynthesis and phytochrome signaling by distinct mechanisms. Plant Cell (2007) 1.73
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 1.67
Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem (2006) 1.64
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics (2005) 1.64
Statistical methods for analyzing right-censored length-biased data under cox model. Biometrics (2009) 1.58
Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res (2008) 1.55
Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry (2004) 1.53
Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc Natl Acad Sci U S A (2002) 1.52
Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem (2002) 1.52
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
A protocol for designing siRNAs with high functionality and specificity. Nat Protoc (2007) 1.49
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (2007) 1.48
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol (2010) 1.47
Functional organization of a neural network for aversive olfactory learning in Caenorhabditis elegans. Neuron (2010) 1.43
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol (2012) 1.42
Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther (2002) 1.42
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther (2011) 1.36
A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer (2004) 1.35
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther (2008) 1.34
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem (2006) 1.33
Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett (2004) 1.33
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A (2008) 1.33
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther (2007) 1.31
Functional profiling reveals that only a small number of phytochrome-regulated early-response genes in Arabidopsis are necessary for optimal deetiolation. Plant Cell (2006) 1.31
Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett (2004) 1.30
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Transcriptomic and genomic evolution under constant cold in Antarctic notothenioid fish. Proc Natl Acad Sci U S A (2008) 1.26
Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J Mol Biol (2003) 1.26
Artificial tertiary motifs stabilize trans-cleaving hammerhead ribozymes under conditions of submillimolar divalent ions and high temperatures. RNA (2004) 1.26
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res (2006) 1.24
p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One (2012) 1.22
Marginal analysis of correlated failure time data with informative cluster sizes. Biometrics (2007) 1.22
Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR (2013) 1.17
Improvement of xylose fermentation in respiratory-deficient xylose-fermenting Saccharomyces cerevisiae. Metab Eng (2011) 1.12
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc (2003) 1.11
Phytochrome phosphorylation modulates light signaling by influencing the protein-protein interaction. Plant Cell (2004) 1.11
Mechanistic insights aid computational short interfering RNA design. Methods Enzymol (2005) 1.09
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des (2007) 1.08
Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev (2009) 1.08
Nonparametric tests for right-censored data with biased sampling. J R Stat Soc Series B Stat Methodol (2010) 1.07
Different delivery methods-different expression profiles. Nat Methods (2005) 1.05
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc Natl Acad Sci U S A (2014) 1.04
Binding of manganese(II) to a tertiary stabilized hammerhead ribozyme as studied by electron paramagnetic resonance spectroscopy. RNA (2005) 1.04
T cell–derived inducible nitric oxide synthase switches off Th17 cell differentiation. J Exp Med (2013) 1.03
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther (2004) 1.03
A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Anal Biochem (2011) 1.03
Maximum Likelihood Estimations and EM Algorithms with Length-biased Data. J Am Stat Assoc (2011) 1.02
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma (2007) 1.02
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett (2010) 1.02
Myopia-related fundus changes in Singapore adults with high myopia. Am J Ophthalmol (2013) 1.02
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol Cancer Ther (2005) 1.02